Restatement of Net Asset Value(s)
Source: RNS
10 February 2026
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Restatement of Net Asset Value(s)
The Board of International Biotechnology Trust plc (the "Company") announces that, due to an administrative error relating to the non-accrual of the Company's most recent interim dividend, the Company's unaudited cum income net asset value ("NAV") per share has been restated for the following dates, as follows:
|
Date |
Published Cum Income NAV per Share |
Revised Cum Income NAV per Share |
|
29/12/2025 |
1021.50 |
1005.87 |
|
30/12/2025 |
1016.30 |
1000.69 |
|
31/12/2025 |
1024.00 |
1008.35 |
|
02/01/2026 |
1013.20 |
997.59 |
|
05/01/2026 |
998.07 |
982.44 |
|
06/01/2026 |
1004.10 |
988.51 |
|
07/01/2026 |
1035.70 |
1020.10 |
|
08/01/2026 |
1025.30 |
1009.67 |
|
09/01/2026 |
1032.20 |
1016.53 |
|
12/01/2026 |
1010.90 |
995.29 |
|
13/01/2026 |
1007.40 |
991.72 |
|
14/01/2026 |
1031.00 |
1015.36 |
|
15/01/2026 |
1021.10 |
1005.51 |
|
16/01/2026 |
1013.60 |
997.96 |
|
19/01/2026 |
1009.70 |
994.04 |
As a result, the Company's service providers have implemented corrective measures and enhanced their procedures.
Enquiries:
Natalia de Sousa
Schroder Investment Management Limited
Tel: 020 7658 6000
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
